-
Mashup Score: 0Home - 16 day(s) ago
Intended Learners The proposed activity is intended for community and academic oncology healthcare professionals (HCPs) who care for patients with EP-NECs, including oncologists, gynecologic oncologists, gastrointestinal oncologists, oncology nurse practitioners (NPs) and physician assistants (PAs), radiologists, pathologists, and pharmacists; as well as allied HCPs who care for patients with EP-NECs. Learning Objectives Delineate the key differences between NETs and NECs, including their respective
Source: hmp-global.swoogo.comCategories: General Medicine NewsTweet
-
Mashup Score: 0Allogeneic Stem Cell Transplantation Beneficial for Patients With High-Risk or R/R Chronic Lymphocytic Leukemia - 19 day(s) ago
Allogeneic stem cell transplantation demonstrated improved survival and cancer outcomes among patients with chronic lymphocytic leukemia, according to a retrospective study.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
Among patients with #CLL, allogeneic stem cell #transplantation demonstrated improved survival and cancer outcomes, according to a retrospective study. Learn more: https://t.co/Q5ziew2RI5 https://t.co/VJz87ZmN8G
-
-
Mashup Score: 0
Treatment with CPX-351 for patients with newly diagnosed secondary acute myeloid leukemia demonstrates real-world efficacy and safety, according to results from a retrospective study.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
Treatment with CPX-351 for patients with newly diagnosed secondary #AML demonstrates real-world efficacy and safety, according to results from a retrospective study. Learn more: https://t.co/iEX03GrLTS https://t.co/tBxExr3XwY
-
-
Mashup Score: 1Home - 20 day(s) ago
Intended Learners The proposed activity is intended for community and academic oncology healthcare professionals (HCPs) who care for patients with EP-NECs, including oncologists, gynecologic oncologists, gastrointestinal oncologists, oncology nurse practitioners (NPs) and physician assistants (PAs), radiologists, pathologists, and pharmacists; as well as allied HCPs who care for patients with EP-NECs. Learning Objectives Delineate the key differences between NETs and NECs, including their respective
Source: hmp-global.swoogo.comCategories: General Medicine NewsTweet-
Extra-pulmonary neuroendocrine carcinoma (EP-NEC) is rare, aggressive, and often misclassified. Join leading experts for a CME/CE-certified webinar covering distinctions from NETs, emerging targets like DLL3, and evolving treatment strategies. Register: https://t.co/9Tf9gx3cB4 https://t.co/GT4B7hiW7b
-
-
Mashup Score: 415Home - 20 day(s) ago
Intended Learners The proposed activity is intended for community and academic oncology healthcare professionals (HCPs) who care for patients with EP-NECs, including oncologists, gynecologic oncologists, gastrointestinal oncologists, oncology nurse practitioners (NPs) and physician assistants (PAs), radiologists, pathologists, and pharmacists; as well as allied HCPs who care for patients with EP-NECs. Learning Objectives Delineate the key differences between NETs and NECs, including their respective
Source: hmp-global.swoogo.comCategories: General Medicine NewsTweet-
EP-NECs and NETs & often confused—but the clinical consequences can be significant. This expert-led webinar will walk through the latest guidance on how to differentiate, diagnose, & treat EP-NEC with confidence. Choose your session: June 23 or June 26. https://t.co/FlZqKZPSMS https://t.co/gPZEWvnJhB
-
-
Mashup Score: 0Belantamab Monotherapy Demonstrates Safety and Durable Responses for Heavily Pretreated R/R MM: Results From DREAMM-20 - 21 day(s) ago
According to interim results from the DREAMM-20 trial, belantamab monotherapy demonstrates safety and efficacy for heavily pretreated patients with relapsed/refractory multiple myeloma.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
According to interim results from the DREAMM-20 trial, #belantamab monotherapy demonstrates safety and efficacy for heavily pretreated patients with relapsed/refractory #MM. Learn more: https://t.co/pb8NY4xXcd https://t.co/tf752h2bvG
-
-
Mashup Score: 1
On June 11, 2025, the US Food and Drug Administration approved taletrectinib for locally advanced or metastatic ROS1-positive non-small cell lung cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
Based on results from the #TRUSTI and #TRUSTII trials, the @US_FDA has approved #taletrectinib for locally advanced or metastatic #ROS1-positive #NSCLC. Learn more: https://t.co/ZzbUrZwqIp #medtwitter #onctwitter #FDAapprovals https://t.co/gCuqOU6EbA
-
-
Mashup Score: 0Irinotecan Liposome Plus Anlotinib Demonstrates Promising Efficacy, Safety in Platinum-Resistant Small Cell Lung Cancer - 22 day(s) ago
According to results from a single-arm, multicenter study, irinotecan liposome plus anlotinib demonstrated promise among patients with platinum-resistant small cell lung cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
According to results from a single-arm, multicenter study, irinotecan liposome plus #anlotinib demonstrated promising clinical efficacy and safety among patients with platinum-resistant #SCLC. Learn more: https://t.co/QVNCVIvXVo #medtwitter #onctwitter #ASCO25 https://t.co/FiWft5ZEoA
-
-
Mashup Score: 0Amulirafusp Alfa Plus Lenalidomide Shows Promising Response Rates for Relapsed/Refractory Follicular Lymphoma - 23 day(s) ago
Amulirafusp alfa demonstrated promising response rates and a manageable safety profile for patients with relapsed/refractory CD20-positive follicular lymphoma, according to data presented at the ASCO Annual Meeting.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
Amulirafusp alfa demonstrated promising response rates and a manageable safety profile for patients with relapsed/refractory CD20-positive #FL, according to data presented at the ASCO Annual Meeting. Learn more: https://t.co/Kj9AyK5K65 https://t.co/P09hfXz2CA
-
-
Mashup Score: 0Subcutaneous Mosunetuzumab Demontrates Promising Efficacy in Previously Untreated High-Tumor Burden FL - 27 day(s) ago
Interim results from the phase 2 MorningSun styudy show fixed-duration subcutaneous mosunetuzumab yields high response rates and manageable safety for patients with previously untreated high-tumor burden follicular lymphoma.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
Interim results from the phase 2 MorningSun styudy show fixed-duration subcutaneous #mosunetuzumab yields high response rates and manageable safety for patients with previously untreated high-tumor burden #FL. Learn more: https://t.co/OuH0cvaSEe https://t.co/DP5fUREmBt
-
EP-NECs & NETs are often confused—but the clinical consequences can be significant. This expert-led webinar will walk through the latest guidance on how to differentiate, diagnose, & treat EP-NEC with confidence. Choose your session: June 23 or June 26. https://t.co/KHZ0Zqs1je https://t.co/fMxF3E58Ub